[1]杨天敬,李 然,苏卫东.CA153、CA125联合HER-2检测在乳腺癌各临床分期诊断中的应用[J].医学信息,2020,33(07):173-174.[doi:10.3969/j.issn.1006-1959.2020.07.058]
　YANG Tian-jing,LI Ran,SU Wei-dong.Application of CA153 and CA125 Combined with HER-2 Detection in the Diagnosis of Breast Cancer in Different Clinical Stages[J].Medical Information,2020,33(07):173-174.[doi:10.3969/j.issn.1006-1959.2020.07.058]
点击复制

CA153、CA125联合HER-2检测在乳腺癌各临床分期诊断中的应用()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年07期
页码:
173-174
栏目:
诊疗技术
出版日期:
2020-04-01

文章信息/Info

Title:
Application of CA153 and CA125 Combined with HER-2 Detection in the Diagnosis of Breast Cancer in Different Clinical Stages
文章编号:
1006-1959（2020）07-0173-02
作者:
杨天敬; 李 然; 苏卫东
（天津市第四中心医院病理科1，检验科2，天津 300140）
Author(s):
YANG Tian-jing; LI Ran; SU Wei-dong
(Department of Pathology1,Department of Laboratory2,Tianjin Fourth Central Hospital,Tianjin 300140,China)
关键词:
肿瘤标志物; CA153; CA125; 乳腺癌; 临床分期
Keywords:
Tumor markers; CA153; CA125; Breast cancer; Clinical stage
分类号:
R737.9；R730.43
DOI:
10.3969/j.issn.1006-1959.2020.07.058
文献标志码:
A
摘要:
目的 分析糖类抗原125（CA125）、糖类抗原153（CA153）联合人类表皮生长因子-2（HER-2）检测在乳腺癌各临床分期诊断中的应用价值。方法 选取2016年5月~2019年5月在我院诊治的200例乳腺癌患者为研究对象，另选取同期体检健康者60名为对照组，比较对照组与乳腺癌各临床分期CA125、CA153及HER-2水平，肿瘤标志物单项检测与三者联合检测的阳性率、敏感性、特异性、准确度。结果 乳腺癌各临床分期患者CA125、CA153、HER-2水平均高于对照组，且Ⅲ期、Ⅳ期乳腺癌患者CA125、CA153、HER-2水平高于Ⅰ~Ⅱ期（P＜0.05）；乳腺癌各临床分期患者CA153+CA125+HER-2联合检测的阳性率高于任一单项检测，且各肿瘤标志物随临床分期的增加阳性率升高（P＜0.05）；乳腺癌患者CA153+CA125+HER-2联合检测的敏感性、准确度高于单项检测（P＜0.05）；CA153+CA125+HER-2联合检测特异性与单项检测比较，差异无统计学意义（P＞0.05）。结论 CA153、CA125、HER-2水平与乳腺癌分期可能有关，且随乳腺癌不同分期增加阳性率逐渐升高，三者联合检测对乳腺癌诊断具有较好的敏感性和准确度。
Abstract:
Objective To analyze the application value of carbohydrate antigen 125 (CA125), carbohydrate antigen 153 (CA153) combined with human epidermal growth factor-2 (HER-2) detection in the clinical staging diagnosis of breast cancer.Methods 200 patients with breast cancer diagnosed and treated in our hospital from May 2016 to May 2019 were selected as the research object, and 60 healthy persons who were healthy during the same period were selected as the control group. Compare the levels of CA125,CA153 and HER-2 in each clinical stage of the control group and breast cancer, the positive rate, sensitivity, specificity and accuracy of single detection of tumor markers and the combined detection of the three. Results The levels of CA125,CA153, and HER-2 in patients with breast cancer in different clinical stages were higher than those in the control group, and the levels of CA125, CA153, and HER-2 in patients with stage III and stage IV breast cancer were higher than those in stages I to II(P<0.05); the positive rate of CA153 + CA125 + HER-2 combined detection of breast cancer patients in each clinical stage was higher than any single test, and the positive rate of each tumor marker increased with the increase of clinical stage(P<0.05); the sensitivity and accuracy of combined detection of CA153 + CA125 + HER-2 in breast cancer patients is higher than that of single detection(P<0.05); The specificity of the CA153 + CA125 + HER-2 combined test was not statistically different from the single test (P>0.05).Conclusion The levels of CA153, CA125 and HER-2 may be related to the stage of breast cancer, and the positive rate gradually increases with the increase of different stages of breast cancer. The combined detection of the three has good sensitivity and accuracy in the diagnosis of breast cancer.

参考文献/References:

[1]胡竞竞,宇晓蕾,翟钥,等.曲妥珠单抗治疗HER-2阳性乳腺癌成本-效果分析及对用药依从性的影响[J].中国药业,2016,25(4):35-37. [2]李宏杰,胡新荣,袁利,等.血清肿瘤标志物CA153、CA125、HER-2检测在乳腺癌诊断中的价值[J].河南外科学杂志,2018,24(1):32-33. [3]詹红泉.CEA CA153 CA125 CA199 CYFRA21-1联合检测乳腺癌的诊断价值[J].浙江临床医学,2016,18(3):555-556. [4]闫建强,聂改红.替吉奥胶囊联合放疗治疗乳腺癌的临床疗效及对肿瘤标志物、人类表皮生长因子受体-2、中期因子水平的影响研究[J].中国临床药理学与治疗学,2017,22(8):899-903. [5]南永刚,许建林,李楠,等.CA153、CA125联合HER-2检测在乳腺癌各临床分期诊断中的应用[J].现代肿瘤医学,2016,24(19):3070-3073.

相似文献/References:

[1]钟 磊,谢海燕,林 霖.电化学发光免疫分析技术检测肿瘤标志物在乳腺癌诊断中的应用[J].医学信息,2018,31(20):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
　ZHONG Lei,XIE Hai-yan,LIN Lin.Application of Electrochemiluminescence Immunoassay for Detection of Tumor Markers in Diagnosis of Breast Cancer[J].Medical Information,2018,31(07):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
[2]兰福全,李秀云,卢 斌.四种肿瘤标志物对肝癌诊断的临床意义[J].医学信息,2018,31(21):164.[doi:10.3969/j.issn.1006-1959.2018.21.048]
　LAN Fu-quan,LI Xiu-yun,LU Bin.The Clinical Significance of Four Tumor Markers in the Diagnosis of Liver Cancer[J].Medical Information,2018,31(07):164.[doi:10.3969/j.issn.1006-1959.2018.21.048]
[3]魏优蕾,郭晓彤.肺癌患者血浆检测肿瘤标志物的分析方法及展望[J].医学信息,2019,32(07):39.[doi:10.3969/j.issn.1006-1959.2019.07.014]
　WEI You-lei,GUO Xiao-Tong.Analytical Methods and Prospects of Plasma Detection of Tumor Markers in Patients with Lung Cancer[J].Medical Information,2019,32(07):39.[doi:10.3969/j.issn.1006-1959.2019.07.014]
[4]杨寿林,宋庆志,吴路发,等.肿瘤标志物和凝血指标在肺癌辅助诊断中的效果分析[J].医学信息,2019,32(07):168.[doi:10.3969/j.issn.1006-1959.2019.07.053]
　YANG Shou-lin,SONG Qing-zhi,WU Lu-fa,et al.Efficacy Analysis of Tumor Markers and Coagulation Parameters in the Diagnosis of Lung Cancer[J].Medical Information,2019,32(07):168.[doi:10.3969/j.issn.1006-1959.2019.07.053]
[5]张东霞.腹腔镜下卵巢子宫内膜样囊肿剥除术对患者肿瘤标志物及卵巢储备功能的影响[J].医学信息,2022,35(13):116.[doi:10.3969/j.issn.1006-1959.2022.13.026]
　ZHANG Dong-xia.Effect of Laparoscopic Ovarian Endometrioid Cystectomy on Tumor Markers and Ovarian Reserve Function[J].Medical Information,2022,35(07):116.[doi:10.3969/j.issn.1006-1959.2022.13.026]
[6]曹 冬.腹腔镜治疗肠癌的效果及对血清CEA水平的影响[J].医学信息,2022,35(16):86.[doi:10.3969/j.issn.1006-1959.2022.16.020]
　CAO Dong.The Effect of Laparoscopic Treatment of Colorectal Cancer and its Effect on Serum CEA Level[J].Medical Information,2022,35(07):86.[doi:10.3969/j.issn.1006-1959.2022.16.020]
[7]杨丽娴.槐耳颗粒联合艾立布林治疗晚期三阴性乳腺癌的真实世界研究[J].医学信息,2023,36(19):144.[doi:10.3969/j.issn.1006-1959.2023.19.032]
　YANG Li-xian.A Real-world Study of Huai’er Granules Combined with Eribulin in the Treatment of Advanced Triple-negative Breast Cancer[J].Medical Information,2023,36(07):144.[doi:10.3969/j.issn.1006-1959.2023.19.032]
[8]刘瀚予,贾莉莉,喻文立,等.外泌体在肝癌中的作用机制研究进展[J].医学信息,2020,33(08):26.[doi:10.3969/j.issn.1006-1959.2020.08.010]
　LIU Han-yu,JIA Li-li,YU Wen-li,et al.The Mechanism of Exosomes in Liver Cancer[J].Medical Information,2020,33(07):26.[doi:10.3969/j.issn.1006-1959.2020.08.010]
[9]侯晓杰.免疫治疗药物对非小细胞肺癌的有效性和安全性研究[J].医学信息,2022,35(18):118.[doi:10.3969/j.issn.1006-1959.2022.18.032]
　HOU Xiao-jie.Study on the Efficacy and Safety of Immunotherapy Drugs for Non-small Cell Lung Cancer[J].Medical Information,2022,35(07):118.[doi:10.3969/j.issn.1006-1959.2022.18.032]
[10]张成宪,李芳玲,马 莹.腹水肿瘤标记物对良恶性腹水的鉴别诊断价值[J].医学信息,2020,33(11):173.[doi:10.3969/j.issn.1006-1959.2020.11.057]
　ZHANG Cheng-xian,LI Fang-ling,MA Ying.Differential Diagnosis Value of Ascites Tumor Markers for Benign and Malignant Ascites[J].Medical Information,2020,33(07):173.[doi:10.3969/j.issn.1006-1959.2020.11.057]

更新日期/Last Update: 2020-04-01